Structural and mechanistic understanding of Unfolded Protein Response (UPR) regulation by ER Hsp70 resident chaperone BIP.
Structural and mechanistic understanding of Unfolded Protein Response (UPR) regulation by ER Hsp70 resident chaperone BIP.
批准号:
MR/L007436/1
负责人:
Maruf Ali
金额:
$26.44万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2014
资助国家:
英国
项目状态:
已结题
起止时间:
2014 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Eukaryotic cell has many compartments that specialises in different functions. One such compartment known as the Endoplasmic Reticulum (ER) specialises inprocessing proteins into their correct shape. In certain types of secretory cells such as antibody producing plasma cells or insulin producing beta cells the requirementto fold these extracellular proteins can increase many fold. The ER has developed a number of strategies to cope with the sudden increase in processing proteins bymaking use of a cell signalling response pathway termed the unfolded protein response, UPR. The initial activation of the UPR is thought to involve a particular region of a sensor protein known as LD. It is thought that LD interacts with a ER resident chaperone protein BIP, that helps to process secretory proteins. There are a number of models that suggest how the presence of incorrectly folded protein leads to activation of the UPR. In this proposal we aim to structurally characterise the interaction between the LD and chaperone protein BIP to understand the mechanism for activating the UPR. A failure or incorrect activation of UPR can lead to many disease states including diabetes, neurodegeneration and cancer. In cancer the solid tumour environment lacks nutrients and oxygen due to the incredible pace at which tumour grows. In order for the tumour to survive this harsh environment the UPR is switched "on". Furthermore in antibody producing plasma cells a downstream component of the UPR has been implicated in multiple myeloma and is dysregulated, therefore inhibition of UPR would help to alleviate this condition. This makes inhibition of UPR an attractive target for anticancer therapeutics.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1126/scitranslmed.aba4627
发表时间:
2021-07-14
期刊:
Science translational medicine
影响因子:
17.1
作者:
[Chrysostomou S, Roy R, Prischi F, Thamlikitkul L, Chapman KL, Mufti U, Peach R, Ding L, Hancock D, Moore C, Molina-Arcas M, Mauri F, Pinato DJ, Abrahams JM, Ottaviani S, Castellano L, Giamas G, Pascoe J, Moonamale D, Pirrie S, Gaunt C, Billingham L, Steven NM, Cullen M, Hrouda D, Winkler M, Post J, Cohen P, Salpeter SJ, Bar V, Zundelevich A, Golan S, Leibovici D, Lara R, Klug DR, Yaliraki SN, Barahona M, Wang Y, Downward J, Skehel JM, Ali MMU, Seckl MJ, Pardo OE]
通讯作者:
Pardo OE
DOI:
10.7554/elife.03522
发表时间:
2015-02-18
期刊:
eLife
影响因子:
7.7
作者:
[Carrara M, Prischi F, Nowak PR, Kopp MC, Ali MM]
通讯作者:
Ali MM
DOI:
10.15252/embj.201489183
发表时间:
2015-06-03
期刊:
The EMBO journal
影响因子:
--
作者:
[Carrara M, Prischi F, Nowak PR, Ali MM]
通讯作者:
Ali MM
ER stress signalling by the UPR activator IRE1 and its regulation by BiP
-
批准号:MR/Y012224/1
-
项目类别:Research Grant
-
资助金额:$77.19万
-
财政年份:2024
-
负责人:Maruf Ali
-
依托单位:
国内基金
海外基金
登录
查看更多内容
酶响应的中性粒细胞外泌体载药体系在眼眶骨缺损修复中的作用及机制研究
-
批准号:82371102
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:苏蕴
-
依托单位:
HIF-1α调控软骨细胞衰老在骨关节炎进展中的作用及机制研究
-
批准号:82371603
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈晓
-
依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
-
批准号:82371631
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:卢慕峻
-
依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
-
批准号:82371150
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:侯书乐
-
依托单位:
TRIM25-PHGDH信号轴调控脓毒症肺上皮细胞铁死亡的机制研究
-
批准号:82372151
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:童尧
-
依托单位:
芍药苷靶向α-烯醇化酶治疗实验性自身免疫性脑脊髓炎的机制研究
-
批准号:82371809
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:聂红
-
依托单位:
脂滴聚集型小胶质细胞介导的髓鞘病变促进小鼠抑郁样行为及其机制研究
-
批准号:82371528
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:李媛
-
依托单位:
基于AMPK/PGC-1α信号轴的工程化外泌体靶向调控BMSCs能量代谢重编程在老年机体骨修复中的作用及其机制研究
-
批准号:82370920
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:周名亮
-
依托单位:
星形胶质细胞介导的髓鞘吞噬参与慢性脑低灌注白质损伤的机制研究
-
批准号:82371307
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:汤耀辉
-
依托单位: